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( -)-[3H]Desmethoxyverapamil (2,7-dimethyl-3-(3,4imethoxyphenyl)-3-cyan-7-~-9-(3-methox~henyl)- 
nonanhydrochloride) was used to label putative Ca *+ channels in guinea pig skeletal muscle. The binding 
sites for ( -)-[3H]desmethoxyverapamil co-purified with t-tubule membrane markers in an established sub- 
cellular fractionation procedure. (-)-[3H]Desmethoxyverapamil bound to partially purified t-tubule mem- 
branes with a Kn of 2.250.1 nM and a B,, of 18*4 pmol/mg membrane protein at 25°C. Binding was 
stereoselectively inhibited by phenylalkylamine Ca2+ antagonists and in a mixed, noncompetitive fashion 
by the benzorhiazepine Cal+ antagonist d-cis-diltiazem and the I+dihydropyridine Ca*+ antagonist 
(+)-PN 200-l 10. Target size analysis of the ( -)-[3H]desmethoxyverapamil drug receptor site revealed a mo- 
lecular mass of 107+2 kDa. In contrast, the target size of the allosterically coupled benzothiazepine drug 
receptor site, labelled by d-ci.r-[3H]diltiazem, was 130.5 +4 kDa @ ~0.01) and of the l,+dihydropyridine 
binding site 179 kDa, when labelled with [3H]nimodipine. It is concluded that ( -)-[3H]desmethoxyverapa- 
mil is an extremely useful radioligand for the phenylalkylamine-selective r ceptor site of the t-tubule local- 
ized Ca2+ channel which is allosterically linked to two other distinct drug receptor sites. 
( -)-[3HJDesmethoxyverapamil Skeletal muscle Caz+-channel Target size 
1. INTRODUCTION 
The inward Ca2+ current of chordate skeletal 
muscle t-tubules is blocked by Ca” antagonists of 
the 1 ,4-dihydropyridine (nifedipine), phenylalkyl- 
amine (D-600) [l] and benzothiazepine (d-cis- 
diltiazem) [2] classes. Putative skeletal muscle 
Ca2+ channels were first labelled directly by the 
1 4-dihydropyridine Ca2’ antagonist [3H]nimodi- 
pine [3] and the structurally unrelated d-cis[3H]- 
diltiazem [4]. Subcellular fractionation experi- 
ments have shown that the high affinity binding 
sites for labelled 1,6dihydropyridines in skeletal 
muscle reside almost exclusively in membranes 
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derived from t-tubules [5,6]. Another drug recep- 
tor site, which is selective for phenylalkylamine 
Ca2+ antagonists, has been recently labelled in 
t-tubule membranes with ( *)-[3H]verapamil [7,8]. 
The KD value of (&)j3H]verapamil is, however, 
high (30-40 nM) which severely limits the useful- 
ness of this channel probe.. An optically pure 
verapamil derivative, (-)-desmethoxyverapamil, 
has been shown to be 20-times more potent than 
verapamil in functional studies [9] and with respect 
to receptor affinity in brain [lo]. Here we describe 
the subcellular distribution of ( - )-[‘HIdesme- 
thoxyverapamil binding sites in skeletal muscle, 
their allosteric regulation through two other 
distinct drug receptor sites of the Ca2’ channel and 
the molecular mass determination of the (-)-[‘HI- 
desmethoxyverapamil drug receptor site with the 
aid of target size analysis. 
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2. MATERIALS AND METHODS 
2.1. Materials 
( -)-[3H]De~methoxyverapamil (83 and 7.2 Ci/ 
mmol), the unlabelled enantiomers of desmethoxy- 
verapamil (code names ( + )- or ( - )-D-888), D-600 
and the biol~ic~ly less potent phenyl~kyl~ine 
derivative (*)-D-619 were gifts from Knoll AG; 
d-cis-[3H]diltiazem (83 Ci/mmol), unlabelled 
d-cis-diltiazem and I-cis-diltiazem were gifts from 
Goedecke AG, ( +)-[3HJPN 200-l 10 (bindability 2 
85%; 75 CUmmol) was from Arnersham. (-)- 
[3H]Dihydroalprenolol (92 Ci/mmol) was from 
New England Nuclear. [3H]Nimodipine (14.5 Ci/ 
mmol) was from Bayer. PN 200-110 enantiamers 
were from Sandoz. 
2.2. Membrane purification 
Partially purified skeletal muscle t-tubule mem- 
branes were prepared as in [3]. SubfractiQnation of 
the partially purified t-tubule membranes was per- 
formed with a discontinuous sucrose density gra- 
dient as in [5]. 
2.3. minding assqs 
These are conducted for ( -)-[3H]desmethox- 
yverapamil in a volume of 0.25 ml in 50 mM Tris- 
HCl, supplemented with 0.1 mM phenylmethylsul- 
fonylfluoride (pH 7.4) at 25*C, allowing 1 h 
before bound and free radioactivity are separated 
through Whatman GF/C filters as described in [3]. 
Binding-inhibition experiments with unlabelled 
drugs were performed with l-2 nM of the 83 Ci/ 
mmol ( -)-[3H]desmethoxyverapamil and lo-20 
pg of partially pulled t-tubule membr~e protein. 
( - )-D-600 and ( - )-desmethoxyverapamil dis- 
placed to the same level of binding when present at 
an approx. 10(X)-fold molar excess over 2 nM ( - )- 
[3H]d~methox~erap~~. In all experiments 
10 FM (-)-D-600 or 1 pM ( - ~-desmethox~er- 
apamil defined ‘blank binding’, which was sub- 
tracted from tatal binding to give specific binding. 
For saturation experiments, high and low specific 
activity ( -}-[3H]desmethox~erap~l were em- 
ployed to allow examination of the saturation iso- 
therm over a wide range of free ligand concentra- 
tions (0.05 to -40 x &). To eVdUate the UatUre of 
competition of various drugs, ( -)-E3H]des- meth- 
ox~erapamil saturation isotherms were construc- 
ted (with the 83 Ci/mmol tracer over the range 0.1 
372 
to -4 x &) in the absence and presence of un- 
labelled drugs. ~3H]Nim~ipine [3], d-c~s-13H]dilti- 
azem binding [4] and [‘Hlouabain binding [3,5,7] 
was performed as previously described. Binding- 
inhibition curves were fitted with non-linear curve 
fitting [l 11 and the kinetics of association with the 
differential form of the second-order ate equation 
t31. 
2.4. Target size anal_vsis 
Partially purified skeletal muscle t-tubule mem- 
branes were irradiated at - 110°C with 10 MeV 
electrons at a dose rate of 2 Mrad/min at a protein 
concentration of 2-3 mg/ml [7,12-141. Radiation 
doses were measured with radiochromic dye films 
(Far West Technology, Goleta, USA). Following 
irradiation, membranes were stored in liquid 
nitrogen for 24 h, then thawed and diluted 1: 30 
for (- )-[3H]desmethoxyverapamil b nding at 0.2 
or 2.0 nM, 1:20 for 13H]nimodipine binding (at 
2 nM) or 1: 10 for d~~-~3H]dilti~em binding (at 
4 nM). We have shown elsewhere that the affinities 
for [3H]nimodipine [12,14] and ( +)-[3H]verapamil 
[7], for residual binding sites are not affected by ir- 
radiation. The same is found for (-)- 
[3H]desmethox~erapamil and dais-[~Hldiltiazem 
binding. The M, values of the irradiated targets 
were calculated according to the relationship de- 
rived in [15] with a temperature correction factor 
m of 2.8 (see [16]), 
l”, =f [$Z4ZJ 
where D37 is the dose of radiation, which reduces 
the binding of a given ligand to 37% of the value 
in a non-irradiated control. 
3, RESULTS 
3.1. ~ubcell~lar distribution of 
( - )-[3H.desmethoxyverapamil binding sites 
Previously it was shown that the binding sites 
for the Ca2+ antagonist [3H)nimodipine in the 
microsomal fraction of guinea pig skeletal muscle 
can be further purified by discontinuous sucrose 
density gradient centrifugation IS]. Membranes, 
collecting at the interface between 25% (w/w) 
sucrose and the overlay, have a specific density of 
-60000 fmol of 1,4-dihydrop~dine receptor sites 
per mg protein. On the basis of protein and 
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phosphoprotein composition, electronmicroscopy 
and marker enzymes, this fraction appears to be 
mainly of t-tubule origin. In table 1 a represen- 
tative experiment of the subfractionation pro- 
cedure is shown. Clearly, the ( -)-[3H]desmethox- 
yverapamil sites copurify with the other Ca2+ 
channel markers and, as previously shown for 
[3H]nimodipine [5,7], (+)-[‘Hlverapamil and d- 
cis-[3H]diltiazem [7], have the highest specific den- 
sity in the t-tubule membrane where fl-adrenocep- 
tors are also enriched. 
3.2. Saturation isotherm and association kinetics 
of ( -)-f3HJdesmetho.qvverapamil 
The association reaction of ( - )-[‘H]desmethox- 
yverapamil with its binding sites followed a rapid 
time course at 25°C. Employing l-2 nM (-)- 
[3H]desmethoxyverapamil and 0.3-0.5 nM drug 
receptor sites, a steady state is reached within 
45 min (fig. 1A). Specific binding was fully reversi- 
ble (not shown). The saturation isotherm of (-)- 
[3H]desmethoxyverapamil binding is monophasic 
with a KD of 2.0 f 0.1 nM and Bmax of 18 f 
4.0 pmol/mg protein at 25°C (n = 10). An exam- 
ple of a typical experiment is shown in f’ig.lB. At 
the KD concentration of free ( -)-[3H]desmethox- 
yverapamil -95% filter-retained radioactivity is 
specific binding. 
3.3. Interaction of ( -)-[3H]desmethoxyverapamil 
labelled sites with Cd’ channel antagonists 
( -)-[3H]Desmethoxyverapamil binding is in- 
hibited stereoselectively by the phenylalkylamine 
Ca2+ antagonists ( - )- and ( + )desmethoxy- 
verapamil and ( - ) and (+)-D-600 (see fig.2). The 
binding inhibition profile for the 1 +dihydropyri- 
dines (+)-PN 200-l 10 and (-)-PN 200-l 10 was 
clearly stereoselective, however ( + )-PN 200-l 10 
was only partially inhibitory up to 100 nM (fig.2) 
even at very low 3H-ligand concentrations. Benzo- 
thiazepines also interacted with the ( -)-[3H]des- 
methoxyverapamil labelled sites stereoselectively. 
The ICSO value of d-cis-diltiazem was 30-times 
lower than that of the biologically inactive [17] l- 
cis-diltiazem. The mode of competition was 
evaluated for the non-phenylalkylamine Ca2+ an- 
tagonists d-cis-diltiazem (fig.3) and the 1 ,Cdihy- 
dropyridine (+ )-PN 200-l 10 (not shown); d-cis- 
diltiazem and (+)-PN 200-l 10 increased, to a 
limited extent, the apparent KD and decreased the 
B ,,,= for ( - )-[‘Hldesmethoxyverapamil, which is 
qualitatively the same result found for (-)- 
Table 1 
Purification of t-tubule membranes from the guinea pig hind limb skeletal muscle 
Calcium channel labels Plasma membrane markers 
(+ H3Hl- [‘HI- (- H3Hl- d-cis-[3H]- Na+K+- fl-Adrenoceptor 
PN 200-l 10 Nimodipine Desmethoxy- Diltiazem ATPase label label 
verapamil [3H]ouabain ( -)-[3H]Di- 
hydroalprenobl 
Fraction Abs. Rel. Abs. Rel. Abs. Rel. Abs. Rel. Abs. Rel. Abs. Rel. 
Homogenate 1440 1 460 1 700 1 91.5 1 109 1 12.9 1 
3500 x pellet g 2557 1.8 831 1.8 1149 1.64 144.4 1.6 364 3.3 34.0 2.6 
45000 x pellet g 10145 7.05 2800 6.1 5275 7.5 671 7.3 708 6.5 31 2.4 
Sucrose gradient 
Fraction 1 12278 8.5 3564 7.7 7063 10.0 1099 12 759 6.9 76.8 5.9 
Fraction 2 15971 11.0 3418 7.4 7352 10.5 1026 11.2 717 6.5 125 9.7 
Fraction 3 5069 3.5 1394 3.03 2197 3.0 318 3.5 1011 9.28 93 7.2 
Fraction 4 32500 22.5 7868 17.1 12973 18.0 2124 23.2 2079 19.1 189 14.6 
See [5,7] for further details. The following radioligands were employed: [3H]ouabain (49 nM), [‘Hlnimodipine 
(2.9 nM), [“H]PN 200-110 (4.8 nM), d-cis-[3H]diltiazem (7.1 nM), ( -)-[3H]dihydroalprenolol (2.05 nM), (-)- 
[3H]desmethoxyverapamil (83 Ci/mmol, 2.19 nM). Fraction 4 consists mainly of t-tubule membranes. abs, specific 
binding in fmol/mg protein; rel, relative specific binding with respect to homogenate (defined as 1.0) 
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Fig. 1. (A) Kinetics of ( -)-[3H]desmethoxyverapamil binding. Partially purified skeletal muscle membranes (4.4/1g in 
0,25 ml) were incubated with 2.98 nM of ( -)-13H]desmethox~erap~l at the indicated times. Blank binding, defined 
by 10 pM (-)-D-600 (0), has been subtracted from total binding to yield specific binding (0). The line through the 
specific binding points is the best fit to the differential form of the second-order ate equation with the parameters 
( f asymptotic SD) k+l, 0.054 f 0.006 nM_’ 3 min-’ and k-r, 0.032 f 0.008 min-‘. (B) Saturation analysis of (-)- 
[3H]d~m~hox~e~p~il. ( -)-[3H]~m~hox~erapam~ (83 Wmmol, 0, A and 7.2 Ci/mmol, l , A) was incubated 
with 13.7 ,ug skeletal muscle partially purified t-tubule membranes for 60 min at 25°C in a volume of 0.25 ml in the 
presence of IOpM (-)-D-600 (A, A, blank binding). The line represents the best fit of the specific binding data to a 
monophasic saturation isotherm with a KD of 2.1 f 0.18 nM and B max. of 793 f 23 pM (equivalent to 14470 -k 
420 fmolimg protein) with a slope factor of 1.08 + 0.10. 
[3H]desmethoxyverapamil 
campus membranes [lo]. 
3.4. Target size analysis 
Radiation inactivation 
labelled sites in hippo- 
experiments of ( -)- 
[3H]desmethox~erap~il drug receptor sites were 
Fig.2. Binding inhibition studies. Z3,, is the specially 
bound ligand in the absence, and 3 in the presence of 
unlabelled drug. IGo (or Ki) values and apparent Hill 
slopes (nu) are given f asymptotic standard deviation. 
For the competitive inhibitors, Ki values were calculated 
taking into account receptor concentration. (A) 
1,4_Dihydropyridines. Binding inhibition studies were 
performed at two different ligand concentrations as 
indicated. At 0.66 nM, ‘H-ligand 53% of high affinity 
binding is inhibited by a saturating con~n~ation of 
(+)-PN 200-l 10, but only 25Yoat 26.5 nM. The ZCSO for 
the inhibitable binding is 2-3 nM at both ligand 
concentrations. At 0.66 nM, ( -)-[3H]desmethoxy- 
verapamil 2 90%‘0 of high affinity binding is inhibited by 
10,uM (-)-PN 200-110, but only 50% at 26.5 nM, 
although the ZCso of (-)-PN 200-l 10 is -500 nM in 
both cases. (B) Phenylalkylamines. (--)-D-aoO: Ki = 12 
*lnM,~~=l.22iO.l~(+)-D~:Ki=55~8nM, 
&I = 1.12 f 0.16; (-)-desmethoxyverapamil: Ki = 3 f 
1 nM, nn = 1.1 f 0.2; (+)-desmethoxyverapamil: Ki = 
17 it 0.9 nM, nn = 0.9 f 0.1; (*)-D-619: Ki = 2855 4 
920 nM, rru = 0.84 f 0.18. (C) ~~~~~ep~~, d-&r- 
dihiazem: ZCso = 215 f 23 nM, nu = 1.11 f 0.12; l-c& 
diltiazem: ZCso = 6900 f 600 nM, rrn = 0.93 Jo 0.06. 
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Fig.3. Nature of d-&-diltiazem inhibition. (A) Saturation experiments were performed with (-)- 
[‘HJdesmethoxyverapamil in the absence and presence of d-cisailtiazem with the concentrations indicated. Primary 
reciprocal plots were linear (correlation coefficients > 0.95). (B) Apparent KD’ and apparent Bmu’ values of the 
radioligand in the presence of d-ci.s-diltiazem were normalized with respect o control KD and B,,,, values. An apparent 
Ki for d-cis-diltiazem was calculated as follows: I[cu/(l-cu)] was plotted against hot ligand concentration (I is the 
concentration of d-cis-diltiazem and cy the ratio of bound hot ligand in the presence of the inhibitor to that in its absence) 
and extrapolated by linear regression to hot ligand = 0. The Ki was 153 nM. (1) Measured data for B- ratio; (2) ratio 
of Bm, ‘/B,,,, in the theoretical case of competitive inhibition; (3) measured ratio of KD’/KD; (4) calculated ratios of 
KD’/KD for Ki = 153 nM using KD’/KD = l/Kr + 1, for the theoretical case of competitive inhibition. 
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Fig.4. Radiation inactivation of the 3 drug receptor sites of the Ca’+-channel. Data is pooled from 3-5 independent 
irradiations. The drawn lines have been calculated by linear regression analysis. (A) The decay of [3H]nimodipine 
binding sites (179 f 8 kDa). (B) The decay of d-&[‘H]diltiazem binding sites (130.5 f 4 kDa). (C) The decay of (-)- 
[“H]desmethoxyverapamil labelled sites (A) (107 f 2 kDa), and the decay of (t))-verapamil labelled sites in one 
experiment performed in parallel with one of the experiments contributing to the ( -)-[3H]desmethoxyverapamil data 
(A). 
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performed with partially purified t-tubule mem- 
branes. In parallel the target sizes of the benzothi- 
azepine- and 1,4-dihydropyridine-selective sites 
were measured. Endogenous acetylcholinesterase 
activity was used as an internal control. The 
molecular mass of the acetylcholinesterase was 72 
f 3 kDa (not shown), in excellent agreement with 
our previous studies 17,13,14]. That of the ( - )- 
[%I]desmethoxyverapamil labelled site (fi8.4) was 
107 f 2 kDa (n = 3), which is smaller than that of 
the d-cis-diltiazem-selective binding site (130.5 f 
4 kDa, n = 3, p < 0.02) or the l,~dihydrop~i~ne 
site, labelled with PH]nimodipine. In one experi- 
ment the inactivation of the phenylalkylamine 
drug receptor site, labelled with ( r+_)-[3H]verapa- 
mil, was evaluated in the same samples. The 
molecular mass was found to be 109 kDa, in ex- 
cellent agreement with what we reported in [6] and 
clearly identical to that of the ( -)-[3H]desmethox- 
yverapamil abelled site. 
4. DISCUSSION 
( -)-[‘HlDesmethoxyverapamil is an extremely 
useful radioligand to study phenyl~kyl~ine 
selective drug receptor sites of the putative Ca” 
channel not only in brain [lo] but also in skeletal 
muscle (here). (- )-['HlDesmethoxyverapamil is 
an optically pure enantiomer and has a 20-times 
lower KD than racemic [‘Hfverapamil. Unlike (*)- 
j3H]verapamil 171, ( - )-~3H]desm~hox~erapamil 
binding can be studied with a good signal to noise 
ratio at 25°C where equilibrium is rapidly reached. 
The stereoselective inhibition of (-)- 
~3HJdesmethox~erapamil binding by D-600 enan- 
tiomers correlates well with the stereoselectivity to 
block K+-induced contractions of skeletal muscle 
[ 181. The biologically weakly active phenylalkyl- 
amine (*)-D-619 [19] is also of low affinity. 
Further, d-cab-dilti~em is of higher potency than 
1-cis-diltiazem to inhibit ( - )-[3H]desmethoxy- 
verapamil binding correlating with the potencies of 
the two diastereoisomers in functional Ca*’ an- 
tagonistic tests 1173. 
The subcellufar fractionation experiments how 
that the ( -)-[3H]desmethox~erap~il receptor 
sites are localized in the t-tubule where D-600, 
nifedipine [l] and d-cis-diltiazem [2] blockable 
Ca2+-currents have been recorded. It has been pro- 
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posed that Ca” channels in brain [10,20] skeletal 
muscle [3,7] and in heart f2lj have 3 distinct, 
reciprocally allosterically coupled drug receptor 
sites. In skeletal muscle and brain [lo] we find that 
d-cis-diltiazem and ( + )-PN 200-l 10 act by binding 
t sites distinct from the phenylalkylamine drug 
receptor site labelled by ( - )-[3H]desmethox- 
yverapamil. The mode of binding-inhibition 
argues against he hypothesis [22] that the channel 
has only two receptor sites (one for the 
1 ,4-dihydropyridines and one where d-cis- 
diltiazem and phenylalkylamihes bind competi- 
tively) . 
The concept of 3 distinct drug receptor sites of 
the Ca2+ channel is also supported at a structural 
level by the radiation inactivation experiments. 
Thus, the molecular mass of the phenylalkylamine 
selective site is 110 kDa with ( +)-[3H]verapamil 
[71 or 107 kDa with ( -)-[3H]desmethox- 
yverapamil, despite the fact that the latter ligand 
labelled only 50% of the sites seen by the racemic 
ligand. These molecular masses are smaller than 
those of the benzothiazepine (130.5 kDa) or 
1 ,Cdihydropyridine (179 kDa, labelled with 
[‘Hlnimodipine) selective sites of the Ca’+-chan- 
nel. Our finding that the distinct drug receptor 
sites of the Ca2+-channel have different target size 
analysis molecular masses is analogous to the 
results reported for the benzodiazepine receptor- 
GABA receptor-chloride ionophore complex in 
radiation inactivation experiments: A molecular 
mass of 54 kDa for the ~unitr~epam-labelled 
subunit has been reported for the benzodiazepine 
receptor, but 135 kDa was found for the allosteri- 
tally coupled site labelled with t-butylcyclophos- 
phoro[3sSJthionate 1231. Also, it is interesting to 
note that the molecular mass of our d-cis-dilti- 
azem-labelled rug receptor site is -2- times larger 
than the decrease of -60 kDa of the l,Cdihydro- 
pyridine drug receptor induced by pre-incubation 
of membranes with d-cis-diltiazem [13,14]. This 
suggests that the channel component, dissociated 
by d-cis-diltiazem, may not be the drug receptor 
for d-cis-diltiazem. Recently it was shown (using 
Na+/K+-ATPase as an example [24]) that multi- 
functional oligomeric complexes when irradiated 
with 10 MeV electrons may exhibit ‘radiation-sen- 
sitive domains’ within a given polypeptide chain. 
This means that the molecular masses obtained for 
given binding sites (or enzymic function, etc.) may 
Volume 176, number 2 FEBS LETTERS October 1984 
in fact be smaller than those of the polypeptide on 
which they reside. 
At the moment, however, the subunit composi- 
tion of the Ca*+-channel is not known with certain- 
ty. An arylazide 1 ,Cdihydropyridine, t3H]azido- 
pine [25] photoincorporates specifically into a 
polypeptide of 145 f 5 kDa of guinea pig skeletal 
muscle t-tubule Ca*+-channels. Further, a poly- 
peptide of 130-160 kDa has been shown to co- 
purify with pre-labelled [3H]nitrendlpine sites of 
rabbit skeletal muscle [26] (in addition to two 
smaller polypeptides of -55 and -30 kDa). A 
satisfactory interpretation of our target size 
analysis results can only be given when the channel 
has been conclusively purified to homogeneity and 
the subunits to which the chemically distinct 
groups of Ca*+ antagonists bind have been sepa- 
rated and individually identified by selective photo- 
affinity labelling. Nevertheless, the results ob- 
tained so far with target size analysis point to an 
oligomeric channel structure and underline funda- 
mental differences in the way the Ca*+-channel in- 
teracts with 1,6dihydropyridine, phenylalkyl- 
amine and benzothiazepine Ca’+-channel blocking 
agents. 
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